德国拜耳利伐沙班服用途中可以直接停药吗？

(Rivaroxaban) is a new type of oral anticoagulant. Compared with traditional anticoagulants such as warfarin, it is easy to use orally, has a stable dosage, does not require constant monitoring, predictable pharmacokinetics, accurate anticoagulant efficacy, and a low risk of causing bleeding, especially intracranial hemorrhage. Its status in the latest anticoagulation guidelines at home and abroad is gradually rising. So, can I stop taking Bayer Rivaroxaban directly while taking it?

German Bayer Rivaroxaban cannot be stopped directly while taking it, because in order to continue to benefit from it, patients need to persist in taking the medication. Until the patient is unable to benefit from it or develops severe side effects, the patient can stop treatment with rivaroxaban based on the professional advice of the doctor.

Germany's Bayer Rivaroxaban is the world's first clinically applied inhibitor that directly acts on coagulation factor Xa. Since inhibitors of coagulation factor

Bayer Group has always adhered to the corporate mission of "Technology creates a better life", carried out research and development activities on a global scale, and invested heavily in research and development to extend the life of patients. Especially in terms of prescription drugs, we focus on research and development in areas with great medical demand. Under the guidance of such a corporate culture, Bayer Healthcare attaches great importance to technology and accumulates experience, making research and development once the core competitiveness of Bayer Healthcare's multinational development, such as hemophilia, multiple sclerosis, contrast agents, etc. In addition to the research and development of new drugs, Bayer Healthcare also focuses on improving existing products and exploring new potential. As a drug owned by Germany's Bayer, its launch has undoubtedly brought new opportunities and choices for the treatment of many patients. Moreover, the drug has relatively significant efficacy and is a trustworthy product.

Recommended hot articles: /newsDetail/86329.html